These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


591 related items for PubMed ID: 20148243

  • 1. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
    Yu NH, Ho EN, Wan TS, Wong AS.
    Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Screen and confirmation of PEG-epoetin β in equine plasma.
    Chang Y, Maylin GM, Matsumoto G, Neades SM, Catlin DH.
    Drug Test Anal; 2011 Jan; 3(1):68-73. PubMed ID: 21254454
    [Abstract] [Full Text] [Related]

  • 5. Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control.
    Guan F, Uboh CE, Soma LR, Birks E, Chen J, You Y, Rudy J, Li X.
    Anal Chem; 2008 May 15; 80(10):3811-7. PubMed ID: 18380469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Doping control analysis of filgrastim in equine plasma and its application to a co-administration study of filgrastim and recombinant human erythropoietin in the horse.
    Ho EN, Kwok WH, Lau MY, Wong AS, Lam KK, Stewart BD, Wan TS.
    J Chromatogr A; 2014 Apr 18; 1338():92-101. PubMed ID: 24636755
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization.
    Groleau PE, Desharnais P, Coté L, Ayotte C.
    J Mass Spectrom; 2008 Jul 18; 43(7):924-35. PubMed ID: 18563860
    [Abstract] [Full Text] [Related]

  • 13. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid.
    Wilber RL.
    Sports Med; 2002 Jul 18; 32(2):125-42. PubMed ID: 11817997
    [Abstract] [Full Text] [Related]

  • 14. A new analytical method based on anti-EPO monolith column and LC-FAIMS-MS/MS for the detection of rHuEPOs in horse plasma and urine samples.
    Bailly-Chouriberry L, Cormant F, Garcia P, Lönnberg M, Szwandt S, Bondesson U, Popot MA, Bonnaire Y.
    Analyst; 2012 May 21; 137(10):2445-53. PubMed ID: 22454833
    [Abstract] [Full Text] [Related]

  • 15. Testing for recombinant erythropoietin.
    Delanghe JR, Bollen M, Beullens M.
    Am J Hematol; 2008 Mar 21; 83(3):237-41. PubMed ID: 17918255
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing.
    Kuuranne T, Thomas A, Leinonen A, Delahaut P, Bosseloir A, Schänzer W, Thevis M.
    Rapid Commun Mass Spectrom; 2008 Mar 21; 22(3):355-62. PubMed ID: 18181226
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry.
    Stübiger G, Marchetti M, Nagano M, Reichel C, Gmeiner G, Allmaier G.
    Rapid Commun Mass Spectrom; 2005 Mar 21; 19(5):728-42. PubMed ID: 15700237
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 30.